JP6971946B2 - 反応抑制的抗体による特異的プラスミン不活性化 - Google Patents

反応抑制的抗体による特異的プラスミン不活性化 Download PDF

Info

Publication number
JP6971946B2
JP6971946B2 JP2018177525A JP2018177525A JP6971946B2 JP 6971946 B2 JP6971946 B2 JP 6971946B2 JP 2018177525 A JP2018177525 A JP 2018177525A JP 2018177525 A JP2018177525 A JP 2018177525A JP 6971946 B2 JP6971946 B2 JP 6971946B2
Authority
JP
Japan
Prior art keywords
plasmin
monoclonal antibody
pharmaceutical composition
functional fragment
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018177525A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019055949A (ja
JP2019055949A5 (enExample
Inventor
エル． リード，ガイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2019055949A publication Critical patent/JP2019055949A/ja
Publication of JP2019055949A5 publication Critical patent/JP2019055949A5/ja
Application granted granted Critical
Publication of JP6971946B2 publication Critical patent/JP6971946B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2018177525A 2017-09-21 2018-09-21 反応抑制的抗体による特異的プラスミン不活性化 Active JP6971946B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762561332P 2017-09-21 2017-09-21
US62/561,332 2017-09-21

Publications (3)

Publication Number Publication Date
JP2019055949A JP2019055949A (ja) 2019-04-11
JP2019055949A5 JP2019055949A5 (enExample) 2021-10-28
JP6971946B2 true JP6971946B2 (ja) 2021-11-24

Family

ID=63678447

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018177525A Active JP6971946B2 (ja) 2017-09-21 2018-09-21 反応抑制的抗体による特異的プラスミン不活性化

Country Status (3)

Country Link
US (1) US11066482B2 (enExample)
EP (1) EP3459974B1 (enExample)
JP (1) JP6971946B2 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230220112A1 (en) * 2019-10-28 2023-07-13 Monash University Antibodies for binding plasmin
CA3250857A1 (en) * 2022-05-04 2023-11-09 Univ Bonn Rheinische Friedrich Wilhelms VHH BINDING TO PLASMINE

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004045558A2 (en) 2002-11-18 2004-06-03 President And Fellows Of Harvard College Compositions and methods for treating thrombotic disorders
EP2753359B1 (en) * 2011-09-06 2018-02-28 Translational Sciences Inc. Serpinf2-binding molecules and methods of use
EP2948167A4 (en) 2013-01-22 2016-10-19 Univ Tennessee Res Foundation TISSUE CLASMINE ACTIVATOR ANTIBODIES AND METHOD OF USE THEREOF
CN105612183A (zh) 2013-07-15 2016-05-25 诺和诺德股份有限公司 结合尿激酶纤溶酶原激活物的抗体

Also Published As

Publication number Publication date
JP2019055949A (ja) 2019-04-11
US20190085097A1 (en) 2019-03-21
US11066482B2 (en) 2021-07-20
EP3459974A1 (en) 2019-03-27
EP3459974B1 (en) 2025-02-19
EP3459974C0 (en) 2025-02-19

Similar Documents

Publication Publication Date Title
US20240398914A1 (en) Combination therapy using a factor xii inhibitor and a c-1 inhibitor
US9574013B2 (en) Antibodies against factor XII and uses thereof
US12065481B2 (en) Therapy using a factor XII inhibitor in a neurotraumatic disorder
JP6971946B2 (ja) 反応抑制的抗体による特異的プラスミン不活性化
JP7509787B2 (ja) 抗血栓症作用および抗炎症作用を有する、第ｘｉ因子に対する新規ヒト化抗体およびその使用
KR20230030644A (ko) 항-단백질 단일-도메인 항체 및 이를 포함하는 폴리펩타이드
TW201437229A (zh) 抗活化蛋白ｃ之人化單株抗體及其用途
Zhao et al. Termination of bleeding by a specific, anticatalytic antibody against plasmin
JP7704339B2 (ja) フィブリンクロットを溶解させることに適した融合タンパク質および当該融合タンパク質を含む医薬組成物
ES2784842T3 (es) Objetivo dual de TAFI y PAI-1
WO2025213043A1 (en) Matrix metalloproteinase-9 inhibitor and treatment of stroke
WO2025133128A1 (en) Adamts13 cub domain variants and uses thereof
CN118922548A (zh) 与纤维蛋白结合的抗体、含有该抗体的纤维蛋白溶解性蛋白质和含有该蛋白质的药物制剂
WO2019005948A1 (en) INHIBITION OF VASCULAR MATRIX METALLOPROTEINASE 9 TO TREAT ISCHEMIC INJURY
HK1220132B (en) Combination therapy using a factor xii inhibitor and a c1-inhibitor
HK1232804B (en) Therapy using a factor xii inhibitor in a neurotraumatic disorder
TW201609808A (zh) 抗活化蛋白ｃ之人類化單株抗體之抗原決定區基因定位及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210917

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210917

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20210917

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20211026

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20211102

R150 Certificate of patent or registration of utility model

Ref document number: 6971946

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250